# BPC-157 Dosage: Protocols Used in Preclinical Research

> BPC-157 dosage ranges studied in preclinical models: 10 pg/kg to 200 μg/kg across multiple routes. Half-life, formulations, stability, and oral vs. injectable data. No human dose recommendations.

**Research-context only.** Every dose cited below was administered to rodents or dogs in a controlled laboratory setting. No dose recommendation for human use is contained here or anywhere on this site.

## Dose Ranges Across Rodent Models

- **Standard efficacy range:** 10 μg/kg intraperitoneal (most common); 10 ng/kg intraperitoneal (1,000-fold lower, also effective in many models).
- **Ultra-low dose:** 10 pg/kg intraperitoneal showed activity in some tendon healing models [4].
- **High single dose (spinal cord model):** 200 μg/kg administered as a single intraperitoneal injection 10 minutes post-injury [14].
- **Oral (drinking water):** 0.16 μg/mL ad libitum (NSAID toxicity model) [9]; 10 μg/kg/day or 10 ng/kg/day (2025 quadriceps study) [7]; 10 μg/kg or 10 ng/kg oral (MCL healing study) [5].

## BPC-157 Half-Life and Pharmacokinetics

**Xu et al. 2022 — dedicated pharmacokinetic study:**

- Rat IV t½ = 15.2 min at 20 μg/kg
- Rat IM bioavailability: 14–19%; IM t½: 7.87–29.7 min dose-dependently
- Dog IM bioavailability: 45–51%; IM t½: 20–29 min
- Primary elimination route: urinary excretion [22]

Older literature citing a "4-hour plasma half-life" is not supported by this dedicated pharmacokinetic study — a common citation error in secondary sources.

No validated human pharmacokinetic data has been published.

## Oral vs. Injectable BPC-157: Bioavailability in Research Models

For gut-localized endpoints, oral administration is effective — consistent with the compound's unusual acid stability (the proline-rich core resists rapid degradation in gastric acid).

For systemic endpoints: multiple oral-route studies have documented systemic effects — MCL healing, muscle-to-bone reattachment, and behavioral endpoints — at oral doses comparable to IP efficacy doses [5, 7, 9].

In the MCL healing study, oral (drinking water), intraperitoneal, and topical cream routes all produced comparable healing outcomes [5].

## BPC-157 Acetate vs. Arginine Salt Formulations

The acetate salt (BPC-157 acetate) is the form used in virtually all published research.

The arginine salt (BPC-157 Arg) has been proposed for oral delivery. No peer-reviewed head-to-head bioavailability comparison has been published.

**Storage:** Lyophilized powder — stable at room temperature short-term; refrigeration preferred. Reconstituted solution — refrigeration required; use within 30 days.

## Routes of Administration Studied

Intraperitoneal, intramuscular, intravenous, oral gavage, oral via drinking water, subcutaneous, topical cream, local injection at injury site, local injection in nerve tubing, intraosseous local injection.

Multi-route efficacy is documented in several head-to-head comparisons within studies [5, 13].

## References

[4] Krivic A, et al. J Orthop Res. 2006;24(5). https://pubmed.ncbi.nlm.nih.gov/16583442/
[5] Cerovecki T, et al. J Orthop Res. 2010;28(9). https://pubmed.ncbi.nlm.nih.gov/20225319/
[7] Matek D, et al. Pharmaceutics. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/
[9] Ilic S, et al. Life Science. 2011;88(11-12). https://pubmed.ncbi.nlm.nih.gov/21295044/
[13] Gjurasin M, et al. Regul Pept. 2010;160(1-3). https://pubmed.ncbi.nlm.nih.gov/19903499/
[14] Perovic D, et al. J Orthop Surg Res. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6604284/
[15] Sikiric P, et al. J Physiol Paris. 2000;94(2):99-104.
[22] Xu X, et al. Front Pharmacol. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/

---

Neon-lit readouts from the peer-reviewed BPC-157 record — every stat logged, every citation indexed, no clinic behind the terminal.